FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to obstetrics and can be used in the 3rd trimester of pregnancy for predicting clinical effectiveness in severe gestosis. Substance of the invention consists in that starting from 28 weeks of pregnancy peripheral venous blood of a woman suffering from severe gestosis is analysed for the content of CD16+CD3-cells. If the related values are less than 9%, conventional therapy of severe gestosis is predicted as efficient, while the value 9% or more show the absence of clinical effectiveness in gestosis.
EFFECT: application of the method allows predicting effectiveness of conventional therapy in severe gestosis from 28 weeks of pregnancy with high accuracy, sensitivity and specificity that enable to determine approach to further prenatal care and delivery, to reduce risk of fetal pathology, maternal and perinatal mortality.
1 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING THE EFFECTIVENESS OF THE TREATMENT OF MODERATE PREECLAMPSIA | 2019 |
|
RU2705374C1 |
| METHOD FOR PREDICTING EFFECTIVENESS OF TREATMENT OF MODERATE PREECLAMPSIA | 2020 |
|
RU2752715C1 |
| METHOD FOR PREDICTING LIGHT-DEGREE GESTOSIS SINCE EARLY TERMS OF PREGNANCY | 2004 |
|
RU2265221C2 |
| METHOD FOR PREDICTION OF CEREBRAL ISCHEMIA IN NEWBORNS BORN TO MOTHERS WITH PREECLAMPSIA | 2023 |
|
RU2819655C1 |
| METHOD FOR FORECASTING SEVERITY OF EARLY PREECLAMPSY | 2021 |
|
RU2753463C1 |
| METHOD OF DIAGNOSING SEVERE PREECLAMPSIA | 2015 |
|
RU2587781C1 |
| METHOD FOR PREDICTING GESTOSIS DEVELOPMENT | 2000 |
|
RU2191384C2 |
| METHOD FOR PREDICTION OF THE RISK OF DEVELOPING SEVERE COMPLICATIONS OF PREECLAMPSIA | 2020 |
|
RU2741730C1 |
| METHOD FOR PREDICTING PREGNANCY OUTCOME IN THREATENING PREMATURE BIRTH CASES | 2004 |
|
RU2272574C2 |
| METHOD OF DIAGNOSTICS OF PREECLAMPSIA ATTACHMENT IN PREGNANT WOMEN WITH CHRONIC ARTERIAL HYPERTENSION | 2016 |
|
RU2652447C1 |
